

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

McMahon, K; Lin, H; Castillo, Lesley; Lee, B; Chatfield, Mark; Lee_Ng, M; Chiam, K; Breit, S; Brown, David; Molloy, M; Marx, Gavin; Pavlakis, Nick; Boyer, Michael; Stockler, Martin; Daly, R; Henshall, Susan; Horvath, L

Published in:
British Journal of Cancer

DOI:
[10.1038/bjc.2015.74](https://doi.org/10.1038/bjc.2015.74)

Published: 31/03/2015

Document Version
Publisher's PDF, also known as Version of record

[Link to publication](#)

Citation for published version (APA):

McMahon, K., Lin, H., Castillo, L., Lee, B., Chatfield, M., Lee_Ng, M., Chiam, K., Breit, S., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Daly, R., Henshall, S., & Horvath, L. (2015). Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. *British Journal of Cancer*, 112(8), 1340-1348. <https://doi.org/10.1038/bjc.2015.74>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Keywords: castration-resistant prostate cancer; docetaxel chemotherapy; cytokines; therapeutic response; macrophage

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

K L Mahon^{1,2,3}, H-M Lin², L Castillo², B Y Lee², M Lee-Ng⁴, M D Chatfield⁵, K Chiam², S N Breit⁴, D A Brown⁴, M P Molloy⁶, G M Marx⁷, N Pavlakis⁸, M J Boyer^{1,3}, M R Stockler^{1,3}, R J Daly⁹, S M Henshall² and L G Horvath^{*1,2,3}

¹Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia; ²Cancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia; ³University of Sydney, Sydney, New South Wales 2050, Australia; ⁴St Vincent's Centre for Applied Medical Research, Liverpool Street, Darlinghurst, NSW 2010, Australia; ⁵Menzies School of Health Research, Darwin, NT, Australia; ⁶Australian Proteome Analysis Facility, Macquarie University, NSW 2105, Australia; ⁷Northern Haematology and Oncology Group, SAN Clinic, Wahroonga, NSW 2076, Australia; ⁸Royal North Shore Hospital, Pacific Highway, Sydney, NSW 2065, Australia and ⁹Signalling Network Laboratory, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, VIC 3800, Australia

Background: Docetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ~50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance *in vitro* and in a clinical cohort.

Methods: PC3 cells or their docetaxel-resistant subline (PC3Rx) were co-cultured with U937 monocytes, with and without docetaxel treatment, and cytokine levels were measured. The circulating levels of 28 cytokines were measured pre-/post cycle 1 of docetaxel from 55 men with CRPC, and compared with prostate-specific antigen (PSA) response.

Results: PC3Rx-U937 co-culture expressed more cytokines, chiefly markers of alternative macrophage differentiation, compared with PC3-U937 co-culture. Docetaxel treatment enhanced cytokine production by PC3Rx-U937 co-culture, while reducing cytokine levels in PC3-U937. In patients, changes in the levels of seven circulating cytokines (macrophage inhibitory cytokine 1 (MIC1), interleukin (IL)-1ra, IL-1 β , IL-4, IL-6, IL-12 and IFN γ) after cycle 1 of docetaxel were associated with progressive disease (all $P < 0.05$). The combination of changes in MIC1, IL-4 and IL-6 most strongly predicted PSA response ($P = 0.002$).

Conclusions: *In vitro* studies suggest docetaxel resistance is mediated, at least in part, by cytokines induced by the interaction between the docetaxel-resistant tumour cells and macrophages. Early changes in circulating cytokine levels were associated with docetaxel resistance in CRPC patients. When considered together, these data suggest a significant role for the inflammatory response and macrophages in the development of docetaxel resistance in CRPC.

Prostate cancer is the most common cancer in men and the third leading cause of male cancer death in the developed world (Jemal *et al*, 2011). Although it is initially sensitive to hormonal manipulation, resistance to androgen deprivation therapy ultimately occurs. In the setting of advanced castration-resistant disease, docetaxel chemotherapy provides modest symptomatic and survival benefits at the cost of significant toxicity (Petrylak

et al, 2004; Tannock *et al*, 2004). However, 50% of patients will not respond to cytotoxic treatment. The decision to cease therapy is made after two to three chemotherapy cycles, as the median time to serum prostate-specific antigen (PSA) response for docetaxel is 44 days (Berthold *et al*, 2008). To minimise unwarranted toxicity and allow earlier progression to other potentially effective therapeutic agents such as cabazitaxel,

*Correspondence: Professor LG Horvath; E-mail: lisa.horvath@lh.org.au

Received 4 September 2014; revised 28 January 2015; accepted 30 January 2015; published online 31 March 2015

© 2015 Cancer Research UK. All rights reserved 0007–0920/15

abiraterone and enzalutamide, early markers of treatment response are urgently required.

Inflammation is implicated in all stages of prostate cancer progression, from carcinogenesis (De Marzo *et al*, 2007) through to castration resistance and cytotoxic resistance (Domingo-Domenech *et al*, 2006) in advanced disease. Cross-talk between tumour cells and myeloid neighbours via cytokine mediators is essential to the development of some forms of chemoresistance (Acharyya *et al*, 2012). In particular, tumour-associated macrophages (TAMs) are central participants in the tumour micro-environment, promoting tumour growth, angiogenesis and metastases (Mantovani *et al*, 2006). Baseline serum interleukin-6 (IL-6; Domingo-Domenech *et al*, 2007) and baseline C-reactive protein (Beer *et al*, 2008) have been implicated as biomarkers of chemoresistance in castration-resistant prostate cancer (CRPC). Single baseline cytokine measures are limited by the significant variability between individuals at any given time point (Wong *et al*, 2008). However, we postulate that measuring changes during chemotherapy would control for this interpersonal variability. We previously demonstrated that an increase in macrophage inhibitory cytokine 1 (MIC1) levels after cycle 1 of chemotherapy in men with CRPC was predictive of docetaxel resistance, as opposed to the static baseline MIC1 levels, which were not able to identify non-responders (Zhao *et al*, 2009). A comprehensive cytokine evaluation during therapy has not been previously performed.

The aim of this study was to investigate the role of cytokines and macrophages in docetaxel resistance *in vitro* and the ability of circulating cytokines to predict patient response to chemotherapy treatment and overall survival.

MATERIALS AND METHODS

Cell lines and conditioned media production. The PC3 and U937 cell lines were obtained from the American Type Culture Collection. The docetaxel-resistant cell line, PC3Rx, was developed through serial passage of PC3 with increasing docetaxel (Sanofi-Aventis, Surrey, UK) concentrations as previously described (Zhao *et al*, 2009). The identity of the cell lines was authenticated by CellBank Australia (NSW, Australia). All cell lines were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum, insulin (0.25 IU ml⁻¹), HEPES (10 mM) and gentamicin (20 µg ml⁻¹). U937 cells were differentiated by treating with 100 ng ml⁻¹ phorbol 12-myristate 13-acetate (PMA; Sigma, St Louis, MO, USA) for 24 h and allowed to recover for 96 h before docetaxel treatment. For assays requiring conditioned media from individual cell lines, cells were cultured for 3 days before culture media was replaced with fresh media with or without addition of docetaxel (8 ng ml⁻¹). The conditioned media was collected after 24 h, centrifuged at 1500 g for 5 min and the supernatant was stored at -80 °C. In co-culture experiments, PC3 or PC3Rx cells were seeded together in the same flask with undifferentiated U937 cells. The media was refreshed after 24 h to remove non-adherent cells. Cells were treated with docetaxel (8 ng ml⁻¹) for 24 h on day 3 or 7, for 4- or 8-day experiments, respectively. Conditioned media was collected after 24 h of docetaxel exposure.

***In vitro* cytokine analysis.** The Human Cytokine Array Panel A (R&D Systems, Minneapolis, MN, USA) was used according to the manufacturer's instructions, to quantitate cytokines in conditioned media collected from cell culture experiments. Cytokines measured were C5/C5a, CD40L, GCSF, GMCSF, GRO α , sICAM, I309, IFN γ , IL-1 α , IL-1ra, IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 p70, IL-13, IL-16, IL-17, IL-17E, IL-23, IL-27, IL-32 α , MCP1, MIF, Serpin E1, RANTES, IP10, ITAC, MIP1 α , MIP1 β , SDF1, TNF α and TREM1. The levels of MIC1 in conditioned media was measured

with a GDF15 Quantikine kit (R&D Systems), according to the manufacturer's instructions.

Patient samples. Blood samples for cytokine analysis were collected at baseline before chemotherapy and 3 weeks after the first dose (cycle 1) of chemotherapy just before the second cycle of treatment, from 55 men with metastatic CRPC. Castration-resistant prostate cancer was defined by PSA and/or clinical progression after maximal androgen blockade, with a minimum of 4 weeks having elapsed between the withdrawal of anti-androgens and the commencement of chemotherapy. Serum samples were obtained from 35 patients treated with docetaxel and PI-88, a heparanase inhibitor, on a phase II clinical trial, which showed that addition of PI-88 was comparable with docetaxel alone (Khasraw *et al*, 2010). Plasma samples were obtained from 20 patients receiving single-agent docetaxel. Plasma samples from seven healthy volunteers (two men and five women) were collected on days 1, 22 and 43. Blood samples were collected according to a standardised operating protocol, using BD Vacutainer tubes (BD, Plymouth, UK) containing K₂EDTA for plasma separation, or clot activator and gel for serum separation. Samples were centrifuged at 3000 g for 5 min at room temperature and stored at -80 °C within 30 min of collection.

Serum PSA levels were measured before each cycle of chemotherapy. Prostate-specific antigen response was defined by modified Prostate Cancer Working Group 2 criteria (Buble *et al*, 1999; Scher *et al*, 2008); partial response (PR) was defined as a decrease from baseline by >50% at any time during the treatment course, progressive disease (PD) was defined as an increase in PSA from baseline by >25% in a patient without a prior defined response and stable disease (SD) was defined as change in PSA \leq 50% decrease or \leq 25% increase. Clinical benefit was defined as patients who achieved SD or PR. Overall survival was defined as the time from commencement of chemotherapy to the time of death. Prospective Eastern Cooperative Oncology Group performance status (ECOG PS) assessment and serum alkaline phosphatase (ALP) data were collected, but were not available in all cases. Radiological assessment was inconsistent in our cohort, prohibiting its use as a response criterion.

All patients provided written informed consent and the study was approved by relevant human research ethics review committees (Approval no. 13663).

Cytokine assay. Samples were analysed using the Bio-Plex Pro Human Cytokine 27-plex assay (Bio-Rad, Hercules, CA, USA) on a Luminex platform at the Australian Proteome Analysis Facility. Cytokines (pg ml⁻¹) measured were PDGF, IL-1 β , IP10, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, Eotaxin, β FGF, GCSF, GMCSF, IFN γ , MCP1, MIP1 α , MIP1 β , RANTES, TNF α and VEGF as described previously (Khan, 2012). MIC1 (pg ml⁻¹) was measured using a previously described sensitive immunoassay (Selander *et al*, 2007).

Statistical analysis. Cytokine array signals were analysed using Image J software (Protein Array Analyser, NIH, Bethesda, MD, USA; imagej.nih.gov/ij/) and expressed as fold changes. Plasma/serum cytokine values were transformed to logarithm scale before analysis. MIC1/IL-6/IL-4 model is the addition of changes in these cytokines over one cycle of chemotherapy. Mann-Whitney *U*-test was used to determine the relationship between cytokine levels and PSA response group. Kaplan-Meier analysis and log-rank statistic were used to measure the association between cytokine levels and survival. Cox regression analysis was used for multivariable analysis of baseline MIC1 and established prognostic factors in relation to survival. Receiver operating characteristic (ROC) curve analysis was used to measure the ability of cytokine levels, to predict response and survival. A *P*-value of <0.05 was required for significance and all significance tests were two sided. All statistical

analyses were performed on SPSS software (IBM, Armonk, NY, USA). Heat map was created with GenePattern (<http://www.broadinstitute.org/cancer/software/genepattern/>), using the relative colour scheme.

RESULTS

Docetaxel increases cytokine production in prostate cancer cell line models. Numerous studies have analysed single cytokines in chemoresistance *in vitro* (Pu *et al*, 2004; Wilson *et al*, 2008; Zhao *et al*, 2009); however, this study aimed to assess the broad spectrum of cytokine changes associated with docetaxel resistance *in vitro*. Thirty-seven cytokines were measured in conditioned media from the androgen-independent prostate cancer cell line, PC3, and its docetaxel-resistant derivative, PC3Rx (Lee *et al*, 2014), before and after 24 h of docetaxel treatment. Seventeen of these cytokines were detected in any of the culture media tested (Figure 1A). The basal levels of cytokines secreted by PC3Rx differed from PC3, where PC3Rx generally had lower cytokine levels. Docetaxel treatment induced changes in cytokine secretion, which also differed between PC3 and PC3Rx. The levels of several pro-inflammatory cytokines, such as IFN γ , IL-1 α and RANTES were increased in docetaxel-treated PC3. In contrast, these pro-inflammatory cytokines were generally decreased in PC3Rx (Figure 1A). Interestingly, PC3Rx cells had higher basal levels of IL-10, an anti-inflammatory cytokine, which was further enhanced by docetaxel exposure (Figure 1A).

Monocyte co-culture with docetaxel-resistant prostate cancer cells increased markers of macrophage differentiation. Given that our previous study had identified MIC1 as a potential driver of

docetaxel resistance, we next considered the interaction between macrophages and prostate cancer cells using U937 cells, a promonocytic cell line, which can be induced to terminal macrophage differentiation (Sundstrom and Nilsson, 1976).

We examined the difference in cytokine production between PC3 or PC3Rx cells, with or without U937 co-culture, to assess the interaction between the macrophages and the cancer cells. When PC3 or PC3Rx were cultured together with U937 cells, U937 became adherent and differentiated into macrophages based on their appearance. Compared with PC3 or PC3Rx individual cell line cultures, conditioned media from U937 co-cultured with PC3 or PC3Rx contained reduced amounts of most cytokines (Supplementary Figure 1B and C). However, IL-1ra, a marker of U937 terminal macrophage differentiation (Roux-Lombard *et al*, 1989; Berger *et al*, 1993), and the TAM phenotype (Mantovani *et al*, 2004) was increased up to 3-fold in PC3/U937 co-culture and was markedly increased by up to 76-fold in PC3Rx/U937 co-culture (Supplementary Figure 1B and C). A corresponding reduction in IL-1 α in co-culture, particularly after 8 days, was also seen, further evidence of macrophage differentiation (Figure 1C; Roux-Lombard *et al*, 1989). Cytokines, predominantly implicated in alternative differentiation and migration of macrophages, such as GMCSF, C5/C5a, IL-10, IL-27 and GRO α , were particularly elevated in U937 co-culture with PC3Rx, compared with PC3 (Figure 1B and C). Co-culture with U937 cells reduced pro-inflammatory IFN γ secretion by PC3 and PC3Rx (Supplementary Figure 1B and 1C).

Docetaxel exposure increased cytokine production in macrophage and chemo-resistant prostate cancer co-culture. The next step was to consider the effect of adding docetaxel to the co-cultures of prostate cancer cells and differentiated macrophages.




Figure 1. Comparisons of cytokine levels in conditioned media from PC3 and PC3Rx cultured alone or in co-culture with U937, with or without 24h docetaxel treatment. (A) PC3 and PC3Rx with or without docetaxel (FC, fold change relative to PC3 without docetaxel). (B) PC3-U937 or PC3Rx-U937 co-culture over 4 days, with or without docetaxel treatment on Day 3 (FC, fold change relative to PC3-U937 co-culture without docetaxel). (C) PC3/U937 or PC3Rx/U937 co-culture over 8 days with or without docetaxel treatment on Day 7 (FC, fold change relative to PC3/U937 co-culture without docetaxel)

Cytokine levels in the conditioned media of U937 cells differentiated with PMA were not significantly altered by 24 h docetaxel treatment of the macrophages (Supplementary Figure 1A), indicating that cytokine production by U937 was not affected by docetaxel. In contrast, the levels of numerous cytokines were increased in PC3Rx/U937 co-culture conditioned media following docetaxel exposure (C5/C5a, GCSF, GRO α , IL-1 α and IL-27), whereas a generalised reduction in cytokine levels was observed in the PC3/U937 co-culture (Figure 1B and C). This is in direct contrast to the individual cell line cultures described above, where docetaxel induced cytokine production in the docetaxel-sensitive PC3 cells more than in the docetaxel-resistant PC3Rx cells. Interestingly, after 4 days of co-culture, MIC1, which was not detected in conditioned media of individual cultures, was detected in PC3/U937 co-culture, but not in the PC3Rx/U937 co-culture. However, after 8 days of co-culture to improve macrophage maturity (Berger *et al*, 1993), MIC1 was expressed in the PC3-Rx/U937 co-culture at higher levels than the chemosensitive counterpart. A similar pattern was seen with GMCSF (Figure 1C). These cytokines are associated with macrophage differentiation and the TAM phenotype, suggesting that the feedback mechanism in the chemoresistant co-culture promotes macrophage maturity.

Temporal variability of circulating cytokine levels. Previous clinical studies have assessed the relationship between baseline cytokine levels and response to treatment, but results are discordant (Beer *et al*, 2008). For that reason, we sought to assess the temporal variability of 27 cytokines in 7 healthy volunteers by assessing 3 consecutive blood samples, each taken at 3 weekly intervals. For most detectable cytokines, intersubject variability was greater than intrasubject variability (intraclass correlation coefficient > 0.5, Supplementary Table 1). This reinforced the need to use paired samples rather than a single measure in time.

Patient characteristics. Plasma or serum samples were collected from a cohort of 55 men receiving docetaxel for metastatic CRPC. At a median follow-up of 15 months, median overall survival was 15 months with 84% deceased at the time of data analysis. The

cohort clinical characteristics are summarised in Table 1. The baseline demographics of our cohort were very similar compared with the two, large phase III trials of docetaxel in CRPC, TAX327 (Tannock *et al*, 2004) and SWOG 99-16 (Petrylak *et al*, 2004). However, 64% of patients in our cohort had a fall in PSA \geq 50%, which was higher than the 45%–50% partial PSA response rates in these trials. Our cohort also had a slightly lower rate of bone and visceral/soft tissue metastases, including involvement of lymph nodes.

Changes in seven cytokines predict for chemotherapy response.

The levels of 28 cytokines were quantitated in the plasma and serum samples. Six cytokines (IL-2, IL-15, IL-17, β FGF, GMCSF and MIP1 α) were below the limit of detection in > 50% of samples and were excluded from statistical analysis. The range and median of the cytokine levels in the cohort are shown in Supplementary Table 2. Seven cytokines (IL-1 α , IL-1 β , IL-4, IL-6, IL-12, IFN γ and MIC1) had significantly increased levels after cycle 1 of chemotherapy in patients with PD compared with those with clinical benefit (PR or SD; Figure 2A and B). Baseline cytokine levels were not associated with chemotherapy response, as the levels were not significantly different between the clinical benefit and PD groups of patients ($P > 0.05$). Overall, both the *in vitro* and human data demonstrate an inflammatory response to docetaxel resistance involving pro-inflammatory mediators and cytokines involved in macrophage recruitment, activation and TAM phenotype such as IL-1 α and MIC1.

In order to identify the best model to predict docetaxel resistance, ROC curve analysis was performed. The change in IL-4 alone was the single, most accurate predictor of PD ($P = 0.005$; Figure 2C). Area under the curve values for each of the seven cytokines significantly associated with clinical benefit were at least 0.7 (Supplementary Table S3). The additive model of changes in IL-4, MIC1 and IL-6 had the strongest association with PD ($P = 0.003$; Figure 2D). Although published data from our group and others have identified a direct role for IL-6 and MIC1 in chemoresistance in CRPC (Borsellino *et al*, 1995; Pu *et al*, 2004; Huang *et al*, 2007; Zhao *et al*, 2009), the addition of recombinant human IL-4 (rhIL-4) to androgen-independent prostate cancer cells does not alter docetaxel cytotoxicity (Supplementary Figure 2).

Pre-treatment MIC1 level predicts for overall survival. Circulating MIC1 levels have prognostic utility in all stages of prostate cancer (Brown *et al*, 2009). In our cohort, patients with baseline MIC1 levels greater than the median (5591 pg ml $^{-1}$) had a significantly shorter overall survival ($P < 0.001$, Figure 3A). Although previous studies have established a normal MIC1 level to be below 1070–1150 pg ml $^{-1}$ (Koopmann *et al*, 2004; Selander *et al*, 2007), too few patients in our cohort of metastatic CRPC had normal values to use this as a discriminator. For illustrative purposes, we chose to use the median value as a cut-point for Kaplan–Meier analysis. This showed that baseline MIC1 was a superior prognostic marker to a \geq 30% fall in PSA within 3 months (Figure 3A and B). As a continuous variable on ROC curve analysis, baseline MIC1 was a better predictor of death within 12 months than maximal change in PSA over 3 months (Figure 3C).

In multivariable Cox proportional hazards analysis with available established prognostic factors (Halabi *et al*, 2003; presence of visceral metastases, Gleason score, baseline ALP, baseline Hb, baseline PSA and PSA response to chemotherapy), baseline MIC1 was an independent predictor of overall survival (HR: 2.73, 95% CI: 1.18–6.32; $P = 0.02$; Table 2). The ECOG PS and LDH level were excluded from analysis due to insufficient available data. LDH is not routinely measured as part of Australian practice. Baseline measures of the remaining cytokines were not associated with survival ($P > 0.05$). The additive model of changes

Table 1. Clinicopathologic characteristics of the patient cohort (n = 55)

Characteristics	Number (% or range)
Age at enrolment (median; n = 55)	68 (53–84) years
Median baseline blood levels	
PSA (n = 55)	163 ng ml $^{-1}$ (0.6–3571)
Haemoglobin (n = 55)	127 g l $^{-1}$ (84–162)
ALP (n = 45)	125 U l $^{-1}$ (36–2962)
Metastatic site (n = 55)	
None	4 (7%)
Bone only	30 (55%)
Visceral/soft tissue	8 (15%)
Bone and visceral	13 (23%)
Gleason score at diagnosis (n = 44)	
6	4 (9%)
7	16 (36%)
8	7 (16%)
9	15 (34%)
10	2 (5%)
PSA response to treatment (n = 55)	
PR	35 (64%)
SD	14 (25%)
PD	6 (11%)
Subsequent systemic therapy	
Mitoxantrone	4 (7%)
Abiraterone	3 (5%)

Abbreviations: ALP = alkaline phosphatase; PD = progressive disease; PR = partial response; PSA = prostate-specific antigen; SD = stable disease.




Figure 2. The relationship between changes in cytokine levels after cycle 1 of chemotherapy and chemotherapy response. **(A)** Heat map of changes in seven cytokine levels after cycle 1 that are significantly different between clinical benefit (PR or SD) and PD groups. **(B)** P-values from Mann-Whitney U-test comparing cytokine fold changes (FC) between clinical benefit and PD groups. **(C)** ROC analysis assessing the efficacy of a change in IL4 after cycle 1 to predict PD. **(D)** ROC analysis assessing the efficacy of combined changes in IL4, MIC1 and IL6 levels after cycle 1 to predict PD.

in IL-4, MIC1 and IL-6 was also not associated with overall survival (Table 2).

DISCUSSION

This study demonstrates that chemotherapy resistance both *in vitro* and in patients is associated with an inflammatory response involving cytokines linked to macrophage recruitment and activation. *In vitro*, co-culture of docetaxel-resistant prostate cancer cells with macrophages results in upregulation of secreted inflammatory cytokines compared with docetaxel-sensitive prostate cancer cells. The addition of docetaxel to the co-culture enhances cytokine production. Furthermore, human correlative studies identified a circulating cytokine profile that is associated with treatment response in CRPC patients.

This is the first study to comprehensively evaluate temporal changes in circulating cytokines rather than single measures, which have had limited utility thus far (Beer *et al*, 2008). The clinical and *in vitro* findings suggest a role for pro-inflammatory cytokines and macrophages in the development of docetaxel resistance in CRPC. Patients who respond poorly to chemotherapy (PD) have increased levels of IL-1ra, a marker of macrophage differentiation (Janson *et al*, 1991), which was also produced at higher levels by monocyte co-cultures with docetaxel-resistant prostate cancer cells compared with docetaxel-sensitive cells. Similarly, MIC1, also associated with macrophage function (Wu *et al*, 2010), was increased in patients with PD and in monocyte co-culture with docetaxel-resistant prostate cancer cells compared with docetaxel-sensitive cells.

The cytokine profiles of the *in vitro* cell models and patients are not in exact concordance, which is not surprising as the *in vitro* models do not reflect the contributions by other immune cells and

tissues. For example, IL-4, another cytokine that was significantly elevated in non-responders after one cycle of chemotherapy was not produced by any of the cell lines, indicating that it is likely to be produced by non-tumour cells, such as T cells. *In vitro*, the addition of rhIL-4 to PC-3 cells did not alter their docetaxel sensitivity, suggesting that IL-4 does not have a direct effect on cancer cells to produce chemoresistance. Nevertheless, IL-4 may be involved in the chemoresistance role of macrophages, as it promotes the proliferation of resident macrophages (Jenkins *et al*, 2013).

A central role of IL-4, together with IL-13, is to promote the alternative activation of macrophages (Gordon, 2003) creating a distinct macrophage cellular profile that has been linked to tumour progression. Macrophages can be activated through two main pathways: (1) the classical pathway via response to microbial products or IFN γ -producing M1 macrophages, which are phagocytic and pro-inflammatory, and (2) the alternative pathway via various signals including IL-4- and IL-13-producing M2 macrophages (Gordon, 2003). Tumour-associated macrophages have similar properties to M2 macrophages and are well-described participants in the tumour microenvironment (Mantovani *et al*, 2006). In co-culture with a variety of tumour cells (Hagemann *et al*, 2006; Weigert *et al*, 2007; Honda *et al*, 2011; Muller-Quernheim *et al*, 2012), monocytes adopt this cellular phenotype. High levels of intra-tumoral macrophages in resected localised prostate cancer correlate with increased risk of biochemical recurrence (Gannon *et al*, 2009). *In vivo*, co-inoculation of PC3 xenograft mice with macrophages alternatively activated with IL-4 promoted tumour growth (Craig *et al*, 2008). In other tumours such as breast cancer and myeloma, co-culture with macrophages induces chemoresistance to multiple agents (Zheng *et al*, 2009; Shree *et al*, 2011). Circulating IL-4 has not previously been implicated as a clinical marker of chemoresistance. However, our




Figure 3. Baseline MIC1 levels and change in PSA after chemotherapy as predictors of overall survival. **(A)** Kaplan–Meier analysis demonstrating that a baseline MIC1 level greater than the median confers a poorer overall survival. **(B)** Kaplan–Meier analysis of the relationship between a $\geq 30\%$ decline in PSA at 3 months after commencing chemotherapy and overall survival. **(C)** ROC curve revealing baseline MIC1 level is superior to maximal change in PSA within 3 months in predicting death within 12 months of commencing chemotherapy.

results suggest links to a key role for macrophages in docetaxel resistance in CRPC.

IL-6, also highly correlated with response to treatment in our cohort, has long been directly implicated in chemoresistance, in both preclinical and clinical studies. Inhibition of IL-6 enhances chemosensitivity *in vitro*, whereas exogenous IL-6 inhibits cytotoxic drug-induced apoptosis (Borsellino *et al*, 1995; Pu *et al*, 2004) potentially via the Bcl and Stat signalling pathways (Pu *et al*, 2004). In relation to macrophage activity, IL-6 reciprocally upregulates the expression of MCP1, a chemotactic factor responsible for the recruitment of monocytes and found in high levels in metastatic prostate tumour tissue (Roca *et al*, 2009). In CRPC patients receiving docetaxel chemotherapy, elevated baseline serum IL-6 levels inversely correlate with response, time to progression and prostate cancer-specific and overall survival (Domingo-Domenech *et al*, 2007; Visa *et al*, 2009). A chimeric

anti-IL-6 antibody (CNTO 328) has been shown to inhibit prostate cancer xenograft growth (Smith and Keller, 2001; Wallner *et al*, 2006). However, a randomised phase II study of CNTO 328 or placebo in combination with mitoxantrone was terminated early due to more deaths in the experimental arm (Fizazi *et al*, 2012). Further development of anti-IL-6 therapy in CRPC has failed to progress.

The correlation of MIC1 with docetaxel resistance in our cohort was not unexpected, as it has been previously implicated *in vitro* and clinically. Androgen-independent cell lines, PC3 and DU145, overexpress MIC1 after docetaxel or mitoxantrone exposure (Huang *et al*, 2007). Our group has previously shown that treatment with exogenous MIC1 increases cellular resistance to docetaxel, whereas siRNA knockdown of MIC1 in docetaxel-resistant PC3Rx cells restores chemosensitivity (Zhao *et al*, 2009). In our previous study with a smaller clinical cohort, an increase in

Table 2. Cox proportional hazards model of factors that predict overall survival in men with CRPC receiving docetaxel (n = 55)

Variable	n	Univariable		Multivariable	
		HR (95% CI)	P-value	HR (95% CI)	P-value
Baseline MIC-1 level >median vs ≤median	55	2.819 (1.517–5.240)	0.001	2.728 (1.178–6.32)	0.02
Hemoglobin ^a , g l ⁻¹	55	0.013 (0.001–0.141)	<0.001	0.025 (0.02–0.308)	0.004
Serum alkaline phosphatase ^a , IU l ⁻¹	45	1.688 (1.246–2.286)	0.001	1.34 (0.928–1.936)	0.1
Progressive disease on chemotherapy (PD vs SD + PR)	55	3.462 (1.327–9.037)	0.011	2.288 (0.51–10.36)	0.3
Baseline serum PSA ^a , ng ml ⁻¹	55	1.356 (1.093–1.681)	0.006	1.095 (0.786–1.525)	0.6
Fall in PSA over 12 weeks <30% vs ≥30%	55	2.591 (1.288–5.209)	0.008	1.271 (0.465–3.474)	0.6
Gleason score	44	1.222 (0.887–1.683)	0.2	—	—
Metastatic site	55				
None		0.47 (0.14–2.50)	0.5		
Bone only		1.0			
Visceral/soft tissue		2.64 (1.15–6.10)	0.02	—	—
Bone and visceral		2.82 (1.36–5.83)	0.05		
Change in MIC1/IL-4/IL-6 levels after cycle 1 chemotherapy	55	1.019 (0.882–1.177)	0.8	—	—

Abbreviations: CI = confidence interval; CRPC = castration-resistant prostate cancer; HR = hazard ratio; IL = interleukin; MIC = minimum inhibitory concentration; PD = progressive disease; PR = partial response; PSA = prostate-specific antigen; SD = stable disease.

^aContinuous variable (log normalised).

MIC1 after the first chemotherapy cycle was correlated with chemoresponse and overall survival (Zhao *et al*, 2009). In our current cohort, docetaxel response data were similar; however, the baseline MIC1 was more closely associated with overall survival. These differences are most probably related to the larger patient numbers in the present cohort and the greater homogeneity of therapy. In other cancers, such as glioblastoma multiforme, MIC1 has been implicated in the promotion of tumour-associated M2-type macrophages (Wu *et al*, 2010). The significance of circulating MIC1 in our cohort further highlights the link with macrophage activity.

TAMs and immune responses, in particular the TH2 responses, have been extensively associated with the initiation and progression of cancer. TH2 T cells are stimulated by TAMs and myeloid-derived suppressor cells, resulting in the skewing of adaptive tumour-specific immunity and the development of a tumour microenvironment that predisposes to tumour proliferation (Disis, 2010). The cytokine profiles in the *in vitro* and human data, both identified cytokines involved in TAM activation and inflammation upregulation in docetaxel resistance. Interestingly, a six-gene prognostic model for CRPC based on whole-blood RNA transcript profiling has recently been developed, in which all genes are modulators of the immune system (Ross *et al*, 2012). Furthermore, three of these genes, which are upregulated in poor prognosis disease (*CIQA*, *TIMP1* and *CDKN1A*) drive monocyte differentiation towards the production of tissue macrophages, while the other three downregulated genes (*ABL2*, *ITGAL* and *SEMA4D*) are components of an integrated system required for T-cell motility, antigen surveillance and T-helper cell activity (Ross *et al*, 2012). These immune aberrations are now being targeted successfully by CTLA-4 and PD-1 inhibitors in melanoma (Topalian *et al*, 2012) and therefore may be useful in overcoming docetaxel resistance in CRPC.

Of the dominant cytokines identified in the clinical cohort, *in vitro* evidence suggests that IL-6 and MIC1 directly alter the response of prostate cancer cells to docetaxel and increase macrophage recruitment and alternative differentiation. The involvement of IL-4 is more complex. Although it does not directly influence prostate cancer cell chemoresistance, it may drive docetaxel resistance as a key mediator of resident macrophage differentiation to TAMs.

In conclusion, we have identified cytokines associated with docetaxel resistance in CRPC patients. The *in vitro* and human correlative data suggest a relationship between macrophage-

associated cytokines and docetaxel resistance in CRPC. These results provide the basis for validation of the IL-4/MIC1/IL-6 model as an early therapeutic-response biomarker and propose strategies to overcome docetaxel resistance.

ACKNOWLEDGEMENTS

We thank the Cancer Institute New South Wales, National Health and Medical Research Council, Australian Cancer Research Foundation, Cancer Australia, Prostate Cancer Foundation of Australia, RT Hall Trust, Tour de Cure, and Sydney Catalyst and Cancer Council NSW. We thank the late Robert L Sutherland for his role in the development and support of this project.

REFERENCES

- Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massague J (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. *Cell* **150**(1): 165–178.
- Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, Henner WD, Ryan CW, Venner P, Ruether JD, Chi KN (2008) C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. *Cancer* **112**(11): 2377–2383.
- Berger AE, Carter DB, Hankey SO, McEwan RN (1993) Cytokine regulation of the interleukin-1 receptor antagonist protein in U937 cells. *Eur J Immunol* **23**(1): 39–45.
- Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock IF (2008) Treatment of hormone-refractory prostate cancer with Docetaxel or Mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. *Clin Cancer Res* **14**: 2763–2767.
- Borsellino N, Belledegrun A, Bonavida B (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. *Cancer Res* **55**(20): 4633–4639.
- Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, Zheng SL, Xu J, Isaacs WB, Gronberg H, Breit SN, Wiklund FE (2009) Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. *Clin Cancer Res* **15**(21): 6658–6664.
- Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C,

- Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G *et al.* (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* **17**(11): 3461–3467.
- Craig M, Ying C, Loberg RD (2008) Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis *in vivo*. *J Cell Biochem* **103**(1): 1–8.
- De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG (2007) Inflammation in prostate carcinogenesis. *Nat Rev Cancer* **7**(4): 256–269.
- Disis ML (2010) Immune regulation of cancer. *J Clin Oncol* **28**: 4631–4638.
- Domingo-Domenech J, Martinez-Fernandez A, Garcia-Albeniz X, Fernandez P, Filella X, Gascon P, Mellado B (2007) Correlation of serum interleukin-6 (IL-6) levels with immunohistochemical p65/nuclear factor- κ B (NF- κ B) expression and prediction of the clinical outcome of hormone-independent prostate cancer patients (HIPC) treated with docetaxel (D). *ASCO Meeting Abstracts* **25**(18_suppl): 5075.
- Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campas C, Dang L, Rolfe M, Ross JS, Gascon P, Albanell J, Mellado B (2006) Interleukin 6, a nuclear factor- κ B target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor- κ B inhibition by PS-1145 enhances docetaxel antitumor activity. *Clin Cancer Res* **12**(18): 5578–5586.
- Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR (2012) Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. *Eur J Cancer* **48**(1): 85–93.
- Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F (2009) Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. *J Immunol Methods* **348**(1–2): 9–17.
- Gordon S (2003) Alternative activation of macrophages. *Nat Rev Immunol* **3**(1): 23–35.
- Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, Charles K, Gordon S, Balkwill FR (2006) Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. *J Immunol* **176**(8): 5023–5032.
- Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. *J Clin Oncol* **21**(7): 1232–1237.
- Honda T, Inagawa H, Yamamoto I (2011) Differential expression of mRNA in human monocytes following interaction with human colon cancer cells. *Anticancer Res* **31**(7): 2493–2497.
- Huang CY, Beer TM, Higano CS, True LD, Vessella R, Lange PH, Garzotto M, Nelson PS (2007) Molecular alterations in prostate carcinomas that associate with *in vivo* exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. *Clin Cancer Res* **13**(19): 5825–5833.
- Janson RW, Hance KR, Arend WP (1991) Production of IL-1 receptor antagonist by human *in vitro*-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. *J Immunol* **147**(12): 4218–4223.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. *CA Cancer J Clin* **61**(2): 69–90.
- Jenkins SJ, Ruckerl D, Thomas GD, Hewitson JP, Duncan S, Brombacher F, Maizels RM, Hume DA, Allen JE (2013) IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1. *J Exp Med* **210**(11): 2477–2491.
- Khan A (2012) Detection and quantitation of forty eight cytokines, chemokines, growth factors and nine acute phase proteins in healthy human plasma, saliva and urine. *J Proteomics* **75**(15): 4802–4819.
- Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, Boyce A, Parnis F, Lim V, Harvie R, Marx G (2010) Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. *Ann Oncol* **21**(6): 1302–1307.
- Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Hruban RH, Breit SN, Kinzler KW, Vogelstein B, Goggins M (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. *Clin Cancer Res* **10**(7): 2386–2392.
- Lee BY, Hochgrafe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG, Daly RJ (2014) Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. *Mol Cancer Ther* **13**(1): 190–201.
- Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. *Cancer Metastasis Rev* **25**(3): 315–322.
- Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. *Trends Immunol* **25**(12): 677–686.
- Muller-Quernheim UC, Potthast L, Muller-Quernheim J, Zissel G (2012) Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons *in vitro*. *J Interferon Cytokine Res* **32**(4): 169–177.
- Petrylak DP, Tangen CM, Hussain MH, Lara Jr. PN, Jones JA, Taplin ME, Burch PA, Berry D, Moynour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* **351**(15): 1513–1520.
- Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML (2004) Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. *Prostate* **60**(2): 120–129.
- Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ (2009) CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. *J Biol Chem* **284**(49): 34342–34354.
- Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK (2012) A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. *Lancet Oncol* **13**(11): 1105–1113.
- Roux-Lombard P, Modoux C, Dayer JM (1989) Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. *Cytokine* **1**(1): 45–51.
- Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. *J Clin Oncol* **26**(7): 1148–1159.
- Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, Parpala T, Risteli J, Breit SN, Jukkola-Vuorinen A (2007) Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. *Cancer Epidemiol Biomarkers Prev* **16**(3): 532–537.
- Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA (2011) Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. *Genes Dev* **25**(23): 2465–2479.
- Smith PC, Keller ET (2001) Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. *Prostate* **48**(1): 47–53.
- Sundstrom C, Nilsson K (1976) Establishment and characterization of a human histiocytic lymphoma cell line (U-937). *Int J Cancer* **17**(5): 565–577.
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* **351**(15): 1502–1512.
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, PD Leming, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Szoln M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* **366**(26): 2443–2454.
- Visa L, Pineda E, Farris B, Codony-Servat J, Filella X, Albiol S, Martinez A, Domingo-Domenech JM, Gascon P, Mellado B (2009) Correlation of serum interleukin-6 (IL-6) levels and clinical outcome in hormone-independent (HI) prostate cancer (PC) patients (PTS) treated with docetaxel. *ASCO Meeting Abstracts*. *J Clin Oncol* **27**(15S): e16044.

- Wallner L, Dai J, Escara-Wilke J, Zhang J, Yao Z, Lu Y, Trikha M, Nemeth JA, Zaki MH, Keller ET (2006) Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. *Cancer Res* **66**(6): 3087–3095.
- Weigert A, Tzieply N, von Knethen A, Johann AM, Schmidt H, Geisslinger G, Brune B (2007) Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. *Mol Biol Cell* **18**(10): 3810–3819.
- Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG, Waugh DJJ (2008) Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. *J Pharmacol Exp Ther* **327**(3): 746–759.
- Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS (2008) Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. *Cancer Epidemiol Biomarkers Prev* **17**(12): 3450–3456.
- Wu A, Wei J, Kong LY, Wang Y, Priebe W, Qiao W, Sawaya R, Heimberger AB (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. *Neuro Oncol* **12**(11): 1113–1125.
- Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG (2009) Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. *Cancer Res* **69**(19): 7696–7703.
- Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q (2009) Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. *Blood* **114**(17): 3625–3628.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)